Abstract
Aims
To evaluate the utility of laser microdissection in the comparison of phenotypes and genetic alterations between colon cancer and corresponding liver metastasis in the context of intratumoral heterogeneity.
Methods
Immunohistochemistry was performed on a series of 11 patients surgically treated for colon adenocarcinoma with liver metastases, using antibodies directed against six mucins. Immunohistochemistry was completed by laser microdissection of tumor zones with particular phenotype, luminal zone and invasion front of colon tumors. Microdissected samples were compared on the basis of microsatellite instability and alterations of CTNNB1, KRAS, and TP53.
Results
Our study demonstrated varying mucin expression within tumors, suggesting the existence of phenotypic intratumoral heterogeneity. A common immunohistochemical profile was observed in individual tumors between tumoral subpopulations and corresponding metastases. Nevertheless, the phenotypic characteristics were distinct from one patient to another. Laser microdissection underlined that phenotypic heterogeneity could rely on genotypic heterogeneity, and that some genetic alterations were common to microdissected samples from primary colon tumors and liver metastases.
Conclusion
We illustrated intratumoral heterogeneity of colon cancer using laser microdissection, in combination with immunohistochemical and genotypic tools. This intratumoral heterogeneity could represent a major issue in the search of prognostic biomarkers.
Similar content being viewed by others
References
Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. New York, NY: Wiley-Liss; 2002.
Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995.
Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138–141.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.
Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21:497–503.
Bernards R, Weinberg RA. Metastasis genes: a progression puzzle. Nature. 2002;418:823.
Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526–3535.
D’Arrigo A, Belluco C, Ambrosi A, et al. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer. 2005;115:256–262.
Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res. 2006;66:11089–11093.
Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77–99.
Bresalier RS, Niv Y, Byrd JC, et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest. 1991;87:1037–1045.
Baldus SE, Mönig SP, Hanisch FG, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology. 2002;40:440–449.
Jang KT, Chae SW, Sohn JH, Park HR, Shin HS. Coexpression of MUC1 with p53 or MUC2 correlates with lymph node metastasis in colorectal carcinomas. J Korean Med Sci. 2002;17:29–33.
Leteurtre E, Gouyer V, Rousseau K, et al. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell. 2004;96:145–151.
Truant S, Bruyneel E, Gouyer V, et al. Requirement of both mucins and proteoglycans in cell–cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int J Cancer. 2003;104:683–694.
Leteurtre E, Zerimech F, Piessen G, et al. Relationships between mucinous gastric carcinoma, MUC2 expression and survival. World J Gastroenterol. 2006;12:3324–3331.
Copin MC, Buisine MP, Leteurtre E, et al. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol. 2001;32:274–281.
Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum. 2005;48:1597–1602.
Hamilton SR, Vogelstein B, Kudo S, et al. Carcinoma of the colon and the rectum. In: Hamilton SR, Aaltonen LA, eds. Tumours of the Digestive System. Lyon, France: IARC Press; 2000:105–119.
Hovenberg HW, Davies JR, Herrmann A, Lindén CJ, Carlstedt I. MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions. Glycoconj J. 1996;13:839–847.
Llinares K, Escande F, Aubert S, et al. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma. Mod Pathol. 2004;17:150–157.
Wickström C, Davies JR, Eriksen GV, Veerman EC, Carlstedt I. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J. 1998;334:685–693.
Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257.
Canzian F, Salovaara R, Hemminki A, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res. 1996;56:3331–3337.
Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004;122:61–69.
Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16:403–410.
You JF, Hsieh LL, Changchien CR, et al. Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients. Clin Cancer Res. 2006;12:4244–4250.
Biemer-Hüttmann AE, Walsh MD, McGuckin MA, et al. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res. 2000;6:1909–1916.
Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol. 1996;49:560–564.
Matsuda K, Masaki T, Watanabe T, et al. Clinical significance of MUC1 and MUC2 mucin and p53 protein expression in colorectal carcinoma. Jpn J Clin Oncol. 2000;30:89–94.
Kuwabara A, Watanabe H, Ajioka Y, et al. Alteration of p53 clonality accompanying colorectal cancer progression. Jpn J Cancer Res. 1998;89:40–46.
Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer. 2001;93:346–352.
Fukunari H, Iwama T, Sugihara K, Miyaki M. Intratumoral heterogeneity of genetic changes in primary colorectal carcinomas with metastasis. Surg Today. 2003;33:408–413.
Acknowledgments
The authors thank Ms A. Ketele (INSERM U837), Mrs V. Dumetz, Mrs V. Vervaeck, Ms S. Gosselin, Mr F. Romelard, Mr M. Samyn (Pathology Department), Mrs R.M. Siminski and Mrs M.H. Gevaert (Histology Department) for their technical assistance. The authors acknowledge Drs I. Carlstedt, D. Swallow, and S.K. Batra for providing antibodies.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buob, D., Fauvel, H., Buisine, MP. et al. The Complex Intratumoral Heterogeneity of Colon Cancer Highlighted by Laser Microdissection. Dig Dis Sci 57, 1271–1280 (2012). https://doi.org/10.1007/s10620-011-2023-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-011-2023-1